Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection

Background Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy, has demonstrated durable efficacy and a manageable safety profile in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in the ELIANA pivotal trial and rea...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Weijie Li, Keith J August, Erin M Hall, Dwight E Yin, Rakesh K Goyal, Atif A Ahmed, Grace S Mitchell, Shawn D St. Peter, Terrie G Flatt, Ibrahim A Ahmed, Richard J Hendrickson, G Doug Myers
Format: article
Langue:EN
Publié: BMJ Publishing Group 2021
Sujets:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/ebd8b85ed1f64889854a9550a505497f
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/ebd8b85ed1f64889854a9550a505497f

Documents similaires